BOLD
Boundless Bio, Inc. Common Stock
NASDAQ: BOLD · HEALTHCARE · BIOTECHNOLOGY
$1.46
+0.69% today
Updated 2026-04-30
Market cap
$33.61M
P/E ratio
—
P/S ratio
—
EPS (TTM)
$-2.60
Dividend yield
—
52W range
$1 – $2
Volume
0.2M
Boundless Bio, Inc. Common Stock (BOLD) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2016 | 2017 | 2018 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Revenue growth (YoY) | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | $682000.00 | $942000.00 | $957000.00 | $1.09M | $1.25M |
| Gross profit | — | — | — | $-682000.00 | $-942000.00 | $-957000.00 | $-1.09M | $-1.25M |
| Gross margin | — | — | — | — | — | — | — | — |
| R&D | $48.77M | $75.90M | $104.37M | $19.28M | $37.16M | $42.64M | $55.27M | $44.84M |
| SG&A | $11.28M | $17.27M | $30.00M | $6.02M | $9.31M | $12.16M | $18.00M | $18.71M |
| Operating income | $-60.05M | $-93.18M | $-134.37M | $-25.30M | $-46.47M | $-54.80M | $-73.27M | $-63.55M |
| Operating margin | — | — | — | — | — | — | — | — |
| EBITDA | $-58.09M | $-88.74M | $-121.36M | $-24.62M | $-45.53M | $-53.84M | $-64.28M | $-62.30M |
| EBITDA margin | — | — | — | — | — | — | — | — |
| EBIT | $-59.67M | $-92.48M | $-128.82M | $-25.30M | $-46.47M | $-54.80M | $-65.36M | $-63.55M |
| Interest expense | — | — | — | — | — | — | — | — |
| Income tax | — | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-59.67M | $-90.24M | $-128.82M | $-25.21M | $-45.90M | $-49.43M | $-65.36M | $-58.20M |
| Net income growth (YoY) | — | -51.2% | -42.8% | +80.4% | -82.1% | -7.7% | -32.2% | +11.0% |
| Profit margin | — | — | — | — | — | — | — | — |